MedTrace Logo

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

NCT03075527 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-01-08

Study results available
· View outcomes & findings →

Summary

This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma.

The drugs involved in this study are:

* Durvalumab
* Tremelimumab

Conditions

Interventions

DRUG

Tremelimumab

Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.

DRUG

Durvalumab

Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.

Sponsors & Collaborators

Principal Investigators

  • Mark M. Awad, MD, PhD · Dana-Farber Cancer Institute

  • Biagio Ricciuti, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-10
Primary Completion
2019-06-07
Completion
2024-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03075527 on ClinicalTrials.gov